Allurion Technologies Announces Board Changes and New Officer Compensation
Ticker: ALURW · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1964979
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
TL;DR
Board shakeup at Allurion: Roberts out, Davies in as director & comp chair. New officer pay details released.
AI Summary
Allurion Technologies, Inc. announced on December 30, 2024, the departure of Director David L. Roberts and the election of new director Dr. Jonathan M. L. Davies. The company also appointed Dr. Davies as the Chair of the Compensation Committee and announced a new compensatory arrangement for certain officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board changes and new compensation arrangements can introduce uncertainty regarding future strategic direction and executive incentives.
Key Players & Entities
- Allurion Technologies, Inc. (company) — Registrant
- David L. Roberts (person) — Departing Director
- Dr. Jonathan M. L. Davies (person) — Newly Elected Director and Chair of Compensation Committee
- December 30, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new director at Allurion Technologies, Inc.?
Dr. Jonathan M. L. Davies has been elected as a new director.
What role will Dr. Jonathan M. L. Davies assume on the board?
Dr. Davies will serve as the Chair of the Compensation Committee.
Who has departed from the board of directors?
David L. Roberts has departed from the board of directors.
What is the reported date for these events?
The earliest event reported is dated December 30, 2024.
What other item is mentioned in relation to officers?
A new compensatory arrangement for certain officers is also mentioned.
Filing Stats: 817 words · 3 min read · ~3 pages · Grade level 11.3 · Accepted 2025-01-06 17:28:31
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ALUR The New York Stock E
- $202.50 — mon stock, each at an exercise price of $202.50 per share of common stock ALUR WS T
- $5 billion — of North America, for LivaNova, PLC, a $5 billion global medical device manufacturer head
Filing Documents
- d912660d8k.htm (8-K) — 27KB
- 0001193125-25-002254.txt ( ) — 183KB
- alur-20241230.xsd (EX-101.SCH) — 4KB
- alur-20241230_def.xml (EX-101.DEF) — 13KB
- alur-20241230_lab.xml (EX-101.LAB) — 22KB
- alur-20241230_pre.xml (EX-101.PRE) — 14KB
- d912660d8k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 6, 2025 ALLURION TECHNOLOGIES, INC. By: /s/ Brendan Gibbons Name: Brendan Gibbons Title: Chief Legal Officer